News

Filter

1 to 9 of 20 results

New drugs to boost graft-versus-host disease treatment market by 2018

New drugs to boost graft-versus-host disease treatment market by 2018

15-08-2014

The graft-versus-host disease (GVHD) treatment market value will increase from $297 million in 2013 to…

Adienne PharmaBegedinaBiotechnologyBudenofalkDr Falk PharmaEuropeImmunologicalsJazz PharmaceuticalsMarkets & MarketingMesoblastProchymalUSA

Global regenerative medicine market expected to reach $67 billion by 2020

Global regenerative medicine market expected to reach $67 billion by 2020

15-07-2014

The global regenerative medicine market will reach $67.6 billion by 2020, up from $16.4 billion in 2013…

BiotechnologyGlobalImmunologicalsMarkets & MarketingRegenerative medicineResearchStem cells

Tacrolimus Sandoz gets sole subsidy supply status in New Zealand

Tacrolimus Sandoz gets sole subsidy supply status in New Zealand

07-03-2014

New Zealand’s Pharmaceutical Management Agency PHARMAC has decided to award immunosuppressant drug…

Asia-PacificGenericsImmunologicalsMarkets & MarketingNew ZealandNovartisPricingSandozTacrolimus Sandoz

Pfizer legacy company agrees near half billion dollar settlement with DoJ

31-07-2013

Wyeth Pharmaceuticals, a US pharma rival acquired by US behemoth Pfizer (NYSE:PFE) in 2009, has agreed…

FinancialImmunologicalsLegalMarkets & MarketingNorth AmericaPfizerPharmaceuticalRapamuneWyeth

Lupus therapeutics boast blockbuster hopefuls as R&D continues, says GlobalData

24-06-2013

Lupus therapeutics are lacking, and patients with moderate forms of the disease are greatly underserved,…

BenlystaBiotechnologyBristol-Myers SquibbepratuzumabGlaxoSmithKlineImmunologicalsMarkets & MarketingOrenciaPharmaceuticalRare diseasesResearchUCB

European therapeutic MAbs market to reach over $42 billion in 2018, says F&S

10-10-2012

Efficient resource to therapy of complex disorders with lesser side effects has accelerated growth of…

BiotechnologyImmunologicalsInflammatory diseasesMarkets & MarketingOncologyPharmaceuticalResearch

Abbott/Eisai's Humira has emerged as leading psoriasis agent

07-08-2012

For the treatment of psoriasis, Abbott/Eisai's Humira (adalimumab) has displaced Amgen/Stiefel/Pfizer/Takeda's…

Abbott LaboratoriesAmgenAnti-Arthritics/RheumaticsBiotechnologyEisaiEnbrelGlobalHumiraImmunologicalsJanssenMarkets & MarketingPfizerPharmaceuticalStelara Injection

1 to 9 of 20 results

COMPANY SPOTLIGHT

Menarini

Back to top